|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
|
|
2
|
Arnold M, Abnet CC, Neale RE, Vignat J,
Giovannucci EL, McGlynn KA and Bray F: Global burden of 5 major
types of gastrointestinal cancer. Gastroenterology.
159:335–349.e15. 2020. View Article : Google Scholar
|
|
3
|
Zhan T, Betge J, Schulte N, Dreikhausen L,
Hirth M, Li M, Weidner P, Leipertz A, Teufel A and Ebert MP:
Digestive cancers: Mechanisms, therapeutics and management. Signal
Transduct Target Ther. 10:242025. View Article : Google Scholar
|
|
4
|
Nagtegaal ID, Odze RD, Klimstra D, Paradis
V, Rugge M, Schirmacher P, Washington KM, Carneiro F and Cree IA;
WHO Classification of Tumours Editorial Board, : The 2019 WHO
classification of tumours of the digestive system. Histopathology.
76:182–188. 2020. View Article : Google Scholar
|
|
5
|
Zhu PP, Li XX, Liu JH, Du XL, Su HY and
Wang J: SMARCA4-deficient undifferentiated carcinoma of the
gastrointestinal tract: a clinicopathological and
immunohistochemical study of nine cases. Zhonghua Bing Li Xue Za
Zhi. 51:868–874. 2022.(In Chinese).
|
|
6
|
Tian Y, Xu L, Li X, Li H and Zhao M:
SMARCA4: Current status and future perspectives in non-small-cell
lung cancer. Cancer Lett. 554:2160222023. View Article : Google Scholar
|
|
7
|
Lombardi M, D'Ercole M, Midolo De Luca V,
Chiari M, Spaggiari L and Bertolaccini L: The impact of SMARCA4
loss in non-small cell lung cancer therapy. Heliyon. 11:e411282024.
View Article : Google Scholar
|
|
8
|
Shi M, Pang L, Zhou H, Mo S, Sheng J,
Zhang Y, Liu J, Sun D, Gong L, Wang J, et al: Rare
SMARCA4-deficient thoracic tumor: Insights into molecular
characterization and optimal therapeutics methods. Lung Cancer.
192:1078182024. View Article : Google Scholar
|
|
9
|
Xue Y, Morris JL, Yang K, Fu Z, Zhu X,
Johnson F, Meehan B, Witkowski L, Yasmeen A, Golenar T, et al:
SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by
restricting IP3R3-mediated Ca2+ flux to mitochondria.
Nat Commun. 12:54042021. View Article : Google Scholar
|
|
10
|
Kim J, Jang G, Sim SH, Park IH, Kim K and
Park C: SMARCA4 depletion induces cisplatin resistance by
activating YAP1-mediated epithelial-to-mesenchymal transition in
triple-negative breast cancer. Cancers (Basel). 13:54742021.
View Article : Google Scholar
|
|
11
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar
|
|
12
|
Locher C, Batumona B, Afchain P, Carrère
N, Samalin E, Cellier C, Aparicio T, Becouarn Y, Bedenne L, Michel
P, et al: Small bowel adenocarcinoma: French intergroup clinical
practice guidelines for diagnosis, treatments and follow-up (SNFGE,
FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Dig Liver Dis.
50:15–19. 2018. View Article : Google Scholar
|
|
13
|
Kelly RJ, Bever K, Chao J, Ciombor KK, Eng
C, Fakih M, Goyal L, Hubbard J, Iyer R, Kemberling HT, et al:
Society for Immunotherapy of Cancer (SITC) clinical practice
guideline on immunotherapy for the treatment of gastrointestinal
cancer. J Immunother Cancer. 11:e0066582023. View Article : Google Scholar
|
|
14
|
Liu H, Hong Q, Zheng S, Zhang M and Cai L:
Effective treatment strategies and key factors influencing
therapeutic efficacy in advanced SMARCA4-deficient non-small cell
lung cancer. Lung Cancer. 198:1080222024. View Article : Google Scholar
|
|
15
|
Chen T, Chen X, Zhang S, Zhu J, Tang B,
Wang A, Dong L, Zhang Z, Yu C, Sun Y, et al: The genome sequence
archive family: Toward explosive data growth and diverse data
types. Genomics Proteomics Bioinformatics. 19:578–583. 2021.
View Article : Google Scholar
|
|
16
|
CNCB-NGDC Members and Partners, . Database
resources of the national genomics data center, china national
center for bioinformation in 2022. Nucleic Acids Res. 50(D1):
D27–D38. 2022. View Article : Google Scholar
|
|
17
|
Saura C, Roda D, Roselló S, Oliveira M,
Macarulla T, Pérez-Fidalgo JA, Morales-Barrera R, Sanchis-García
JM, Musib L, Budha N, et al: A First-in-human phase I study of the
ATP-competitive AKT inhibitor ipatasertib demonstrates robust and
safe targeting of AKT in patients with solid tumors. Cancer Discov.
7:102–113. 2017. View Article : Google Scholar
|
|
18
|
Therkildsen C, Bergmann TK,
Henrichsen-Schnack T, Ladelund S and Nilbert M: The predictive
value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment
in metastatic colorectal cancer: A systematic review and
meta-analysis. Acta Oncol. 53:852–864. 2014. View Article : Google Scholar
|
|
19
|
Wang ZH, Gao QY and Fang JY: Loss of PTEN
expression as a predictor of resistance to anti-EGFR monoclonal
therapy in metastatic colorectal cancer: Evidence from
retrospective studies. Cancer Chemother Pharmacol. 69:1647–1655.
2012. View Article : Google Scholar
|
|
20
|
Forster MD, Dedes KJ, Sandhu S, Frentzas
S, Kristeleit R, Ashworth A, Poole CJ, Weigelt B, Kaye SB and
Molife LR: Treatment with olaparib in a patient with PTEN-deficient
endometrioid endometrial cancer. Nat Rev Clin Oncol. 8:302–306.
2011. View Article : Google Scholar
|
|
21
|
Koehler K, Liebner D and Chen JL: TP53
mutational status is predictive of pazopanib response in advanced
sarcomas. Ann Oncol. 27:539–543. 2016. View Article : Google Scholar
|
|
22
|
Chalhoub N and Baker SJ: PTEN and the
PI3-kinase pathway in cancer. Annu Rev Pathol. 4:127–150. 2009.
View Article : Google Scholar
|
|
23
|
Milella M, Falcone I, Conciatori F, Cesta
Incani U, Del Curatolo A, Inzerilli N, Nuzzo CM, Vaccaro V, Vari S,
Cognetti F and Ciuffreda L: PTEN: Multiple functions in human
malignant tumors. Front Oncol. 5:242015. View Article : Google Scholar
|
|
24
|
Seshacharyulu P, Ponnusamy MP, Haridas D,
Jain M, Ganti AK and Batra SK: Targeting the EGFR signaling pathway
in cancer therapy. Expert Opin Ther Targets. 16:15–31. 2012.
View Article : Google Scholar
|
|
25
|
Sigismund S, Avanzato D and Lanzetti L:
Emerging functions of the EGFR in cancer. Mol Oncol. 12:3–20. 2018.
View Article : Google Scholar
|
|
26
|
Bendell JC, Rodon J, Burris HA, de Jonge
M, Verweij J, Birle D, Demanse D, De Buck SS, Ru QC, Peters M, et
al: Phase I, dose-escalation study of BKM120, an oral pan-class I
PI3K inhibitor, in patients with advanced solid tumors. J Clin
Oncol. 30:282–290. 2012. View Article : Google Scholar
|
|
27
|
Weber J and McCormack PL: Panitumumab: In
metastatic colorectal cancer with wild-type KRAS. BioDrugs.
22:403–411. 2008. View Article : Google Scholar
|
|
28
|
Sørensen SG, Shrikhande A, Poulsgaard GA,
Christensen MH, Bertl J, Laursen BE, Hoffmann ER and Pedersen JS:
Pan-cancer association of DNA repair deficiencies with whole-genome
mutational patterns. Elife. 12:e812242023. View Article : Google Scholar
|
|
29
|
Kassem PH, Montasser IF, Mahmoud RM,
Ghorab RA, AbdelHakam DA, Fathi MESA, Wahed MAA, Mohey K, Ibrahim
M, Hadidi ME, et al: Genomic landscape of hepatocellular carcinoma
in Egyptian patients by whole exome sequencing. BMC Med Genomics.
17:2022024. View Article : Google Scholar
|
|
30
|
Watanabe T, Semba S and Yokozaki H:
Regulation of PTEN expression by the SWI/SNF chromatin-remodelling
protein BRG1 in human colorectal carcinoma cells. Br J Cancer.
104:146–154. 2011. View Article : Google Scholar
|
|
31
|
Gouda MA, Janku F, Wahida A, Buschhorn L,
Schneeweiss A, Abdel Karim N, De Miguel Perez D, Del Re M, Russo A,
Curigliano G, et al: Liquid biopsy response evaluation criteria in
solid tumors (LB-RECIST). Ann Oncol. 35:267–275. 2024. View Article : Google Scholar
|
|
32
|
Ebner L, Christodoulidis S, Stathopoulou
T, Geiser T, Stalder O, Limacher A, Heverhagen JT, Mougiakakou SG
and Christe A: Meta-analysis of the radiological and clinical
features of usual interstitial pneumonia (UIP) and nonspecific
interstitial pneumonia (NSIP). PLoS One. 15:e02260842020.
View Article : Google Scholar
|
|
33
|
Zeng X, Yao B, Liu J, Gong GW, Liu M, Li
J, Pan HF, Li Q, Yang D, Lu P, et al: The SMARCA4R1157W
mutation facilitates chromatin remodeling and confers PRMT1/SMARCA4
inhibitors sensitivity in colorectal cancer. NPJ Precis Oncol.
7:282023. View Article : Google Scholar
|
|
34
|
Liang X, Gao X, Wang F, Li S, Zhou Y, Guo
P, Meng Y and Lu T: Clinical characteristics and prognostic
analysis of SMARCA4-deficient non-small cell lung cancer. Cancer
Med. 12:14171–14182. 2023. View Article : Google Scholar
|
|
35
|
Witkowski L, Nichols KE, Jongmans M, van
Engelen N, de Krijger RR, Herrera-Mullar J, Tytgat L, Bahrami A,
Mar Fan H, Davidson AL, et al: Germline pathogenic SMARCA4 variants
in neuroblastoma. J Med Genet. 60:987–992. 2023. View Article : Google Scholar
|
|
36
|
Neil AJ, Zhao L, Isidro RA, Srivastava A,
Cleary JM and Dong F: SMARCA4 mutations in carcinomas of the
esophagus, esophagogastric junction, and stomach. Mod Pathol.
36:1001832023. View Article : Google Scholar
|
|
37
|
Pors J, Devereaux KA, Hildebrandt D and
Longacre TA: Primary uterine synovial sarcoma with SMARCA4 loss.
Histopathology. 80:1135–1137. 2022. View Article : Google Scholar
|
|
38
|
Koyasu S, Sugimoto A, Matsubara J, Muto M
and Nakamoto Y: SMARCA4-deficient poorly differentiated
adenocarcinoma of the gallbladder. Clin Nucl Med. 49:688–689. 2024.
View Article : Google Scholar
|
|
39
|
Akunuru S, James Zhai Q and Zheng Y:
Non-small cell lung cancer stem/progenitor cells are enriched in
multiple distinct phenotypic subpopulations and exhibit plasticity.
Cell Death Dis. 3:e3522012. View Article : Google Scholar
|
|
40
|
Xu J and Chi Z: Esophageal carcinoma with
SMARCA4 mutation: A narrative review for this rare entity. Transl
Gastroenterol Hepatol. 9:242024. View Article : Google Scholar
|
|
41
|
Chang B, Sheng W, Wang L, Zhu X, Tan C, Ni
S, Weng W, Huang D and Wang J: SWI/SNF complex-deficient
undifferentiated carcinoma of the gastrointestinal tract:
Clinicopathologic study of 30 cases with an emphasis on variable
morphology, immune features, and the prognostic significance of
different SMARCA4 and SMARCA2 subunit deficiencies. Am J Surg
Pathol. 46:889–906. 2022. View Article : Google Scholar
|
|
42
|
Wang Y, Meraz IM, Qudratullah M, Kotagiri
S, Han Y, Xi Y, Wang J and Lissanu Y: SMARCA4 mutation induces
tumor cell-intrinsic defects in enhancer landscape and resistance
to immunotherapy. bioRxiv. Jun 22–2024.(Epub ahead of print).
|
|
43
|
Shi YN, Zhang XR, Ma WY, Lian J, Liu YF,
Li YF and Yang WH: PD-1 antibody in combination with chemotherapy
for the treatment of SMARCA4-deficient advanced undifferentiated
carcinoma of the duodenum: Two case reports. World J Clin Oncol.
15:456–463. 2024. View Article : Google Scholar
|
|
44
|
Schoenfeld AJ, Bandlamudi C, Lavery JA,
Montecalvo J, Namakydoust A, Rizvi H, Egger J, Concepcion CP, Paul
S, Arcila ME, et al: The genomic landscape of SMARCA4 alterations
and associations with outcomes in patients with lung cancer. Clin
Cancer. 26:5701–5708. 2020. View Article : Google Scholar
|
|
45
|
Agaimy A, Daum O, Märkl B, Lichtmannegger
I, Michal M and Hartmann A: SWI/SNF complex-deficient
undifferentiated/rhabdoid carcinomas of the gastrointestinal tract:
A series of 13 cases highlighting mutually exclusive loss of
SMARCA4 and SMARCA2 and frequent co-inactivation of SMARCB1 and
SMARCA2. Am J Surg Pathol. 40:544–553. 2016. View Article : Google Scholar
|
|
46
|
Liu J, Song L and Wang J: Primary
SMARCA4-deficient undifferentiated sarcomatoid tumor of the
gastroesophageal junction. Hum Pathol Case Rep. 22:2004322020.
View Article : Google Scholar
|
|
47
|
Wong AK, Shanahan F, Chen Y, Lian L, Ha P,
Hendricks K, Ghaffari S, Iliev D, Penn B, Woodland AM, et al: BRG1,
a component of the SWI-SNF complex, is mutated in multiple human
tumor cell lines. Cancer Res. 60:6171–6177. 2000.
|
|
48
|
Ankoh K, Shinji S, Yamada T, Matsuda A,
Ohta R, Sonoda H, Hotta M, Takahashi G, Kaneya Y, Iwai T, et al: A
rapidly growing small-intestinal metastasis from lung cancer. J
Nippon Med Sch. 89:540–545. 2022. View Article : Google Scholar
|
|
49
|
Xu Y, Zhang B and Wang J: Gastrointestinal
stromal tumour with liver metastasis presenting as gastric cancer.
Diagnostics (Basel). 13:3762023. View Article : Google Scholar
|
|
50
|
Altaf K, Mckernan G, Skaife P and Slawik
S: Splenic metastasis in colorectal cancer. Tech Coloproctol.
20:795–796. 2016. View Article : Google Scholar
|
|
51
|
Li X, Tian S, Shi H, Ta N, Ni X, Bai C,
Zhu Z, Chen Y, Shi D, Huang H, et al: The golden key to open
mystery boxes of SMARCA4-deficient undifferentiated thoracic tumor:
Focusing immunotherapy, tumor microenvironment and epigenetic
regulation. Cancer Gene Ther. 31:687–697. 2024. View Article : Google Scholar
|
|
52
|
Kakkar A, Ashraf SF, Rathor A, Adhya AK,
Mani S, Sikka K and Jain D: SMARCA4/BRG1-deficient sinonasal
carcinoma. Arch Pathol Lab Med. 146:1122–1130. 2022. View Article : Google Scholar
|
|
53
|
Nambirajan A, Singh V, Bhardwaj N, Mittal
S, Kumar S and Jain D: SMARCA4/BRG1-deficient non-small cell lung
carcinomas: A case series and review of the literature. Arch Pathol
Lab Med. 145:90–98. 2021. View Article : Google Scholar
|
|
54
|
Zhou P, Fu Y and Wang W: Case report:
Gastrointestinal neuroendocrine carcinoma with SMARCA4 deficiency:
A clinicopathological report of two rare cases. Front Oncol.
13:12907172023. View Article : Google Scholar
|
|
55
|
Yu L and Wu D: SMARCA2 and SMARCA4
participate in DNA damage repair. Front Biosci (Landmark Ed).
29:2622024. View Article : Google Scholar
|
|
56
|
Berezowska S, Maillard M, Keyter M and
Bisig B: Pulmonary squamous cell carcinoma and lymphoepithelial
carcinoma-morphology, molecular characteristics and differential
diagnosis. Histopathology. 84:32–49. 2024. View Article : Google Scholar
|
|
57
|
Affandi KA, Tizen NMS, Mustangin M and Zin
RRMRM: p40 immunohistochemistry is an excellent marker in primary
lung squamous cell carcinoma. J Pathol Transl Med. 52:283–289.
2018. View Article : Google Scholar
|
|
58
|
Garcia-Porrero G, Wood F, Faria S, Kelly
PJ and McCluggage WG: ‘Aberrant’ expression of skeletal muscle
markers in neuroendocrine carcinomas: A significant diagnostic
pitfall. Virchows Arch. 485:625–629. 2024. View Article : Google Scholar
|
|
59
|
Vocino Trucco G, Righi L, Volante M and
Papotti M: Updates on lung neuroendocrine neoplasm classification.
Histopathology. 84:67–85. 2024. View Article : Google Scholar
|
|
60
|
Watter H, Milkins R, Chambers C and
O'Brien B: Melanoma with rhabdomyosarcomatous features: A potential
diagnostic pitfall. BMJ Case Rep. 16:e2564272023. View Article : Google Scholar
|
|
61
|
Tran TAN, Linos K, de Abreu FB and Carlson
JA: Undifferentiated sarcoma as intermediate step in the
progression of malignant melanoma to rhabdomyosarcoma: Histologic,
histologic, immunohistochemical, and molecular studies of a new
case of malignant melanoma with rhabdomyosarcomatous
differentiation. Am J Dermatopathol. 41:221–229. 2019. View Article : Google Scholar
|
|
62
|
Tuohy JL, Byer BJ, Royer S, Keller C,
Nagai-Singer MA, Regan DP and Seguin B: Evaluation of myogenin and
MyoD1 as immunohistochemical markers of canine rhabdomyosarcoma.
Vet Pathol. 58:516–526. 2021. View Article : Google Scholar
|
|
63
|
Agard H, Clark C, Massanyi E, Steele M and
McMahon D: Chemoradiotherapy-induced cytodifferentiation in
bladder/prostate rhabdomyosarcoma with genetic downregulation of
myogenin and MyoD1 gene expression: A case study and review of the
literature. Urology. 137:173–177. 2020. View Article : Google Scholar
|
|
64
|
Mishra P, Patra S, Srinivasan A, Padhi S,
Sable MN, Samal SC and Mohapatra S: Primary gastrointestinal
anaplastic large cell lymphoma: A critical reappraisal with a
systematic review of the world literature. J Cancer Res Ther.
17:1307–1313. 2021. View Article : Google Scholar
|
|
65
|
Radha S, Afroz T and Reddy R: Primary
anaplastic large cell lymphoma of caecum and ascending colon.
Indian J Pathol Microbiol. 64:168–170. 2021. View Article : Google Scholar
|
|
66
|
Hasegawa T, Matsuno Y, Shimoda T, Umeda T,
Yokoyama R and Hirohashi S: Proximal-type epithelioid sarcoma: A
clinicopathologic study of 20 cases. Mod Pathol. 14:655–663. 2001.
View Article : Google Scholar
|
|
67
|
Echchaoui A, Sadrati Y, Elbir Y, Elktaibi
A, Benyachou M, Mazouz SE, Gharib NE and Abbassi A: Proximal-type
epithelioid sarcoma: A new case report and literature review. Pan
Afr Med J. 24:2382016. View Article : Google Scholar
|
|
68
|
Quintanal-Villalonga Á, Costa E,
Wohlheiter C, Tischfield S, Redin E, Sridhar H, Funnel A, Poirier
JT, Hao Y, Kinyua D, et al: 228P SMARCA4 inactivation drives
aggressiveness in STK11/KEAP1 co-mutant lung adenocarcinomas
through the induction of TGFβ signaling. ESMO Open. 9 (Suppl
3):S1028782024. View Article : Google Scholar
|
|
69
|
An HR, Kim HD, Ryu MH and Park YS:
SMARCA4-deficient undifferentiated gastric carcinoma: A case series
and literature review. Gastric Cancer. 27:1147–1152. 2024.
View Article : Google Scholar
|
|
70
|
Wilson BG and Roberts CWM: SWI/SNF
nucleosome remodellers and cancer. Nat Rev Cancer. 11:481–492.
2011. View Article : Google Scholar
|
|
71
|
Liu L, Ahmed T, Petty WJ, Grant S, Ruiz J,
Lycan TW, Topaloglu U, Chou PC, Miller LD, Hawkins GA, et al:
SMARCA4 mutations in KRAS-mutant lung adenocarcinoma: A
multi-cohort analysis. Mol Oncol. 15:462–472. 2021. View Article : Google Scholar
|
|
72
|
Alessi JV, Ricciuti B, Spurr LF, Gupta H,
Li YY, Glass C, Nishino M, Cherniack AD, Lindsay J, Sharma B, et
al: SMARCA4 and other SWItch/sucrose nonfermentable family genomic
alterations in NSCLC: Clinicopathologic characteristics and
outcomes to immune checkpoint inhibition. J Thorac Oncol.
16:1176–1187. 2021. View Article : Google Scholar
|
|
73
|
Cui M, Lemmon K, Jin Z and Uboha NV:
Esophageal carcinoma with SMARCA4 mutation: Unique diagnostic
challenges. Pathol Res Pract. 248:1546922023. View Article : Google Scholar
|
|
74
|
Yin C, Liu ZJ, He C and Yu HX: A case of
surgically treated non-metastatic SMARCA4-deficient
undifferentiated thoracic tumor: A case report and literature
review. Front Oncol. 14:13998682024. View Article : Google Scholar
|
|
75
|
Bell EH, Chakraborty AR, Mo X, Liu Z,
Shilo K, Kirste S, Stegmaier P, McNulty M, Karachaliou N, Rosell R,
et al: SMARCA4/BRG1 is a novel prognostic biomarker predictive of
cisplatin-based chemotherapy outcomes in resected non-small cell
lung cancer. Clin Cancer Res. 22:2396–2404. 2016. View Article : Google Scholar
|
|
76
|
Dagogo-Jack I, Schrock AB, Kem M, Jessop
N, Lee J, Ali SM, Ross JS, Lennerz JK, Shaw AT and Mino-Kenudson M:
Clinicopathologic characteristics of BRG1-deficient NSCLC. J Thorac
Oncol. 15:766–776. 2020. View Article : Google Scholar
|
|
77
|
Naito T, Umemura S, Nakamura H, Zenke Y,
Udagawa H, Kirita K, Matsumoto S, Yoh K, Niho S, Motoi N, et al:
Successful treatment with nivolumab for SMARCA4-deficient non-small
cell lung carcinoma with a high tumor mutation burden: A case
report. Thorac Cancer. 10:1285–1288. 2019. View Article : Google Scholar
|
|
78
|
Skoulidis F, Goldberg ME, Greenawalt DM,
Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco
SE, Gay L, et al: STK11/LKB1 mutations and PD-1 inhibitor
resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov.
8:822–835. 2018. View Article : Google Scholar
|
|
79
|
Leinonen HM, Kansanen E, Pölönen P,
Heinäniemi M and Levonen AL: Dysregulation of the keap1-Nrf2
pathway in cancer. Biochem Soc Trans. 43:645–649. 2015. View Article : Google Scholar
|
|
80
|
Gatalica Z, Xiu J, Swensen J and Vranic S:
Comprehensive analysis of cancers of unknown primary for the
biomarkers of response to immune checkpoint blockade therapy. Eur J
Cancer. 94:179–186. 2018. View Article : Google Scholar
|
|
81
|
Concepcion CP, Ma S, LaFave LM, Bhutkar A,
Liu M, DeAngelo LP, Kim JY, Del Priore I, Schoenfeld AJ, Miller M,
et al: Smarca4 inactivation promotes lineage-specific
transformation and early metastatic features in the lung. Cancer
Discov. 12:562–585. 2022. View Article : Google Scholar
|
|
82
|
Han XJ, Alu A, Xiao YN, Wei YQ and Wei XW:
Hyperprogression: A novel response pattern under immunotherapy.
Clin Transl Med. 10:e1672020. View Article : Google Scholar
|
|
83
|
Misra S, Szeto W, Centeno L, Castillo D,
Rucker A, Rahmanuddin S and Mannan R: SMARCA4 deficient gastric
carcinoma with squamous differentiation in a young patient with
aggressive clinical course. Int J Surg Pathol. 33:1016–1021. 2025.
View Article : Google Scholar
|
|
84
|
Bhat V, Koneru M, Knapp K, Joneja U,
Morrison J and Hong YK: Identification and treatment of SMARCA4
deficient poorly differentiated gastric carcinoma. Am Surg.
89:4987–4989. 2023. View Article : Google Scholar
|
|
85
|
Kido K, Nojima S, Motooka D, Nomura Y,
Kohara M, Sato K, Ohshima K, Tahara S, Kurashige M, Umeda D, et al:
Ovarian high-grade serous carcinoma cells with low SMARCA4
expression and high SMARCA2 expression contribute to platinum
resistance. J Pathol. 260:56–70. 2023. View Article : Google Scholar
|
|
86
|
Mokashi A and Bhatia NM: Integrated
network ethnopharmacology, molecular docking, and ADMET analysis
strategy for exploring the anti-breast cancer activity of ayurvedic
botanicals targeting the progesterone receptor. BIO Integr. 5:1–17.
2024. View Article : Google Scholar
|
|
87
|
Ji X, Tian X, Feng S, Zhang L, Wang J, Guo
R, Zhu Y, Yu X, Zhang Y, Du H, et al: Intermittent F-actin
perturbations by magnetic fields inhibit breast cancer metastasis.
Research (Wash DC). 6:00802023.
|
|
88
|
Guo XF, Gu SS, Wang J, Sun H, Zhang YJ, Yu
PF, Zhang JS and Jiang L: Protective effect of mesenchymal stem
cell-derived exosomal treatment of hippocampal neurons against
oxygen-glucose deprivation/reperfusion-induced injury. World J
Emerg Med. 13:46–53. 2022. View Article : Google Scholar
|
|
89
|
Luo Z, Mei J, Wang X, Wang R, He Z, Geffen
Y, Sun X, Zhang X, Xu J, Wan R, et al: Voluntary exercise
sensitizes cancer immunotherapy via the collagen
inhibition-orchestrated inflammatory tumor immune microenvironment.
Cell Rep. 43:1146972024. View Article : Google Scholar
|
